CorMedix Company Profile (NYSEMKT:CRMD)

About CorMedix (NYSEMKT:CRMD)

CorMedix logoCorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications. Neutrolin is an anti-infective solution for the prevention of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. Neutrolin is a broad-spectrum antimicrobial/antifungal and anticoagulant combination that is active against common microbes, including antibiotic-resistant strains, and may prevent biofilm formation.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:CRMD
  • CUSIP: N/A
  • Web:
  • Market Cap: $16.75 million
  • Outstanding Shares: 40,624,000
Average Prices:
  • 50 Day Moving Avg: $0.43
  • 200 Day Moving Avg: $1.21
  • 52 Week Range: $0.36 - $3.26
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.15
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $222,237.00
  • Price / Sales: 75.35
  • Book Value: $0.27 per share
  • Price / Book: 1.52
  • EBIDTA: ($28,200,000.00)
  • Net Margins: -19,203.39%
  • Return on Equity: -211.19%
  • Return on Assets: -165.43%
  • Average Volume: 426,605 shs.
  • Beta: 0.24
  • Short Ratio: 10.36
Frequently Asked Questions for CorMedix (NYSEMKT:CRMD)

What is CorMedix's stock symbol?

CorMedix trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "CRMD."

How were CorMedix's earnings last quarter?

CorMedix Inc. (NYSEMKT:CRMD) issued its earnings results on Wednesday, November, 9th. The company reported ($0.23) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.08. The business earned $0.04 million during the quarter, compared to the consensus estimate of $0.05 million. CorMedix had a negative return on equity of 211.19% and a negative net margin of 19,203.39%. View CorMedix's Earnings History.

Where is CorMedix's stock going? Where will CorMedix's stock price be in 2017?

2 analysts have issued twelve-month target prices for CorMedix's stock. Their forecasts range from $4.00 to $5.00. On average, they anticipate CorMedix's share price to reach $4.50 in the next year. View Analyst Ratings for CorMedix.

Who are some of CorMedix's key competitors?

Who are CorMedix's key executives?

CorMedix's management team includes the folowing people:

  • Randy Milby, Chief Executive Officer, Director
  • Robert W. Cook, Chief Financial Officer
  • Antony E. Pfaffle M.D., Chief Scientific Officer, Director
  • Judith R Abrams, Chief Medical Officer
  • Khoso Baluch, Director
  • Myron M. Kaplan, Director
  • Mehmood Khan M.D., Director
  • Janet M. Dillione, Independent Director
  • Matthew P. Duffy, Independent Director

Who owns CorMedix stock?

CorMedix's stock is owned by many different of retail and institutional investors. Top institutional investors include Bollard Group LLC (0.99%). Company insiders that own CorMedix stock include Antony Pfaffle, Cora M Tellez, Janet Dillione, Khoso Baluch, Matthew Duffy, Robert W Cook, Steven W Lefkowitz and Taunia Markvicka. View Institutional Ownership Trends for CorMedix.

How do I buy CorMedix stock?

Shares of CorMedix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CorMedix's stock price today?

One share of CorMedix stock can currently be purchased for approximately $0.41.

MarketBeat Community Rating for CorMedix (NYSEMKT CRMD)
Community Ranking:  2.5 out of 5 (  )
Outperform Votes:  78 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  156
MarketBeat's community ratings are surveys of what our community members think about CorMedix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for CorMedix (NYSEMKT:CRMD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.50

Analysts' Ratings History for CorMedix (NYSEMKT:CRMD)
DateFirmActionRatingPrice TargetDetails
5/5/2017Rodman & RenshawLower Price TargetBuy$6.00 -> $5.00View Rating Details
4/24/2017FBR & CoReiterated RatingBuyView Rating Details
11/16/2015Roth CapitalLower Price TargetNeutral$2.75 -> $2.50View Rating Details
11/12/2015HC WainwrightInitiated CoverageBuy$6.50View Rating Details
(Data available from 7/23/2015 forward)


Earnings History for CorMedix (NYSEMKT:CRMD)
Earnings by Quarter for CorMedix (NYSEMKT:CRMD)
Earnings History by Quarter for CorMedix (NYSEMKT CRMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2016Q3 2016($0.15)($0.23)$0.05 million$0.04 millionViewN/AView Earnings Details
8/5/2016Q216($0.11)($0.13)$119.97 million$16.51 millionViewN/AView Earnings Details
5/10/2016Q1($0.09)($0.12)$0.11 million$0.04 millionViewN/AView Earnings Details
11/12/2015Q3($0.13)($0.14)$0.12 million$0.04 millionViewListenView Earnings Details
8/6/2015Q2 2015($0.13)($0.13)$0.08 million$0.12 millionViewN/AView Earnings Details
3/12/2015Q4 2014($0.12)($0.09)$0.08 million$0.09 millionViewN/AView Earnings Details
11/13/2014Q3 2014($0.09)($0.09)$0.08 million$0.05 millionViewN/AView Earnings Details
8/14/2014Q2 2014($0.13)($0.26)$0.02 million$0.04 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for CorMedix (NYSEMKT:CRMD)
Current Year EPS Consensus Estimate: $-0.6000 EPS
Next Year EPS Consensus Estimate: $-0.3600 EPS


Dividend History for CorMedix (NYSEMKT:CRMD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for CorMedix (NYSEMKT:CRMD)
Insider Trades by Quarter for CorMedix (NYSEMKT:CRMD)
Institutional Ownership by Quarter for CorMedix (NYSEMKT:CRMD)
Insider Trades by Quarter for CorMedix (NYSEMKT:CRMD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/30/2017Cora M TellezDirectorBuy7,550$0.42$3,171.00View SEC Filing  
5/17/2017Khoso BaluchCEOBuy75,000$0.48$36,000.00View SEC Filing  
5/16/2017Cora M TellezDirectorBuy50,000$0.48$24,000.00View SEC Filing  
5/15/2017Janet DillioneDirectorBuy21,231$0.48$10,190.88View SEC Filing  
5/15/2017Robert W CookCFOBuy50,000$0.50$25,000.00View SEC Filing  
5/1/2017Cora M TellezDirectorBuy4,800$0.66$3,168.00View SEC Filing  
3/30/2017Cora M TellezDirectorBuy1,950$1.66$3,237.00View SEC Filing  
2/28/2017Cora M TellezDirectorBuy1,540$2.10$3,234.00View SEC Filing  
2/7/2017Antony PfaffleInsiderSell10,000$2.00$20,000.00View SEC Filing  
1/30/2017Cora M TellezDirectorBuy1,780$1.79$3,186.20View SEC Filing  
12/30/2016Cora M TellezDirectorBuy1,990$1.58$3,144.20View SEC Filing  
12/9/2016Khoso BaluchCEOBuy10,000$1.77$17,700.00View SEC Filing  
11/30/2016Cora M TellezDirectorBuy1,800$1.80$3,240.00View SEC Filing  
10/31/2016Cora M TellezDirectorBuy1,475$2.15$3,171.25View SEC Filing  
10/21/2016Antony PfaffleInsiderSell20,000$2.23$44,600.00View SEC Filing  
9/22/2016Janet DillioneDirectorBuy15,000$2.66$39,900.00View SEC Filing  
8/25/2016Taunia MarkvickaDirectorBuy18,600$1.65$30,690.00View SEC Filing  
8/19/2016Cora M TellezDirectorBuy12,500$1.73$21,625.00View SEC Filing  
6/21/2016Antony PfaffleInsiderSell29,657$2.14$63,465.98View SEC Filing  
6/20/2016Antony PfaffleInsiderSell10,000$2.16$21,600.00View SEC Filing  
6/15/2016Antony PfaffleInsiderSell4,900$2.21$10,829.00View SEC Filing  
6/13/2016Antony PfaffleInsiderSell5,443$2.27$12,355.61View SEC Filing  
6/9/2016Antony PfaffleInsiderSell10,000$2.38$23,800.00View SEC Filing  
6/8/2016Janet DillioneDirectorBuy3,738$2.67$9,980.46View SEC Filing  
6/3/2016Matthew DuffyDirectorSell46,106$2.73$125,869.38View SEC Filing  
5/31/2016Steven W LefkowitzDirectorSell50,000$2.88$144,000.00View SEC Filing  
5/25/2016Cora M TellezDirectorBuy8,600$2.90$24,940.00View SEC Filing  
5/24/2016Antony PfaffleInsiderSell12,700$2.73$34,671.00View SEC Filing  
5/24/2016Antony PfaffleInsiderSell12,700$2.73$34,671.00View SEC Filing  
5/23/2016Antony PfaffleInsiderSell15,000$2.89$43,350.00View SEC Filing  
5/23/2016Steven W LefkowitzDirectorSell30,000$2.93$87,900.00View SEC Filing  
5/19/2016Antony PfaffleInsiderSell12,300$2.82$34,686.00View SEC Filing  
5/16/2016Antony PfaffleInsiderSell60,000$2.68$160,800.00View SEC Filing  
6/30/2015Randy MilbyCEOBuy1,610$3.88$6,246.80View SEC Filing  
6/23/2015Taunia MarkvickaDirectorBuy4,000$4.81$19,240.00View SEC Filing  
6/15/2015Randy MilbyCEOBuy1,245$5.02$6,249.90View SEC Filing  
6/4/2015Matthew DuffyDirectorSell30,000$6.48$194,400.00View SEC Filing  
5/29/2015Randy MilbyCEOBuy1,026$6.09$6,248.34View SEC Filing  
2/27/2015Randy MilbyCEOBuy1,211$5.16$6,248.76View SEC Filing  
2/13/2015Randy MilbyCEOBuy1,911$3.27$6,248.97View SEC Filing  
1/30/2015Randy MilbyCEOBuy2,016$3.10$6,249.60View SEC Filing  
12/15/2014Randy MilbyCEOBuy4,734$1.32$6,248.88View SEC Filing  
11/28/2014Randy MilbyCEOBuy4,464$1.40$6,249.60View SEC Filing  
11/14/2014Cora M TellezDirectorBuy11,086$1.52$16,850.72View SEC Filing  
11/14/2014Randy MilbyCEOBuy4,111$1.52$6,248.72View SEC Filing  
10/31/2014Randy MilbyCEOBuy3,434$1.82$6,249.88View SEC Filing  
9/30/2014Randy MilbyCEOBuy3,324$1.88$6,249.12View SEC Filing  
9/15/2014Randy MilbyCEOBuy3,654$1.71$6,248.34View SEC Filing  
8/29/2014Randy MilbyCEOBuy3,125$2.00$6,250.00View SEC Filing  
8/15/2014Randy MilbyCEOBuy3,140$1.99$6,248.60View SEC Filing  
7/31/2014Randy MilbyCEOBuy6,250$2.00$12,500.00View SEC Filing  
6/30/2014Randy MilbyCEOBuy2,732$1.83$4,999.56View SEC Filing  
12/13/2013Steven W LefkowitzInsiderBuy18,000$0.78$14,040.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for CorMedix (NYSEMKT:CRMD)
Latest Headlines for CorMedix (NYSEMKT:CRMD)
DateHeadline logoCorMedix Inc. (NYSEMKT:CRMD) Downgraded by Zacks Investment Research - July 17 at 8:26 PM logoImplied Volatility Surging For CorMedix Inc (CRMD) Stock Options - July 14 at 3:18 PM logoCorMedix Inc. Provides Comprehensive Pipeline Update During Research and Development Day - July 12 at 6:11 PM logoCorMedix Inc. (CRMD) Upgraded to Buy by Zacks Investment Research - July 11 at 9:04 PM logoCorMedix Inc. Appoints Mehmood Khan, M.D. and Steven Lefkowitz to its Board of Directors - June 26 at 5:18 PM logoETFs with exposure to CorMedix, Inc. : June 16, 2017 - June 16 at 5:15 PM logoCormedix, Inc.: CorMedix Inc. to Showcase Its Taurolidine-Based Development Pipeline at Research and Development Day - June 14 at 5:22 PM logoCorMedix Inc. to Showcase Its Taurolidine-Based Development Pipeline at Research and Development Day - June 14 at 5:22 PM logoCorMedix Inc. Announces Changes to Board of Directors - June 12 at 5:29 PM logoINVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of CorMedix, Inc. - May 26 at 5:00 PM logoETFs with exposure to CorMedix, Inc. : May 26, 2017 - May 26 at 5:00 PM logoCorMedix Inc. (CRMD) CEO Purchases $36,000.00 in Stock - May 19 at 8:52 PM logoCorMedix Inc. (CRMD) CFO Acquires $25,000.00 in Stock - May 17 at 8:34 PM logoCorMedix Inc. (CRMD) Director Cora M. Tellez Buys 50,000 Shares - May 17 at 8:34 PM logoCorMedix Inc. (CRMD) Director Janet Dillione Buys 21,231 Shares - May 17 at 8:34 PM logoZacks Investment Research Downgrades CorMedix Inc. (CRMD) to Hold - May 15 at 8:58 PM logoETFs with exposure to CorMedix, Inc. : May 15, 2017 - May 15 at 4:23 PM logoCorMedix, Inc. :CRMD-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 - May 12 at 5:02 PM logoCormedix, Inc.: CorMedix Inc. Reports First Quarter Financial Results and Provides Business Update - May 10 at 9:43 PM logoCorMedix Inc. Reports First Quarter Financial Results and Provides Business Update - May 10 at 4:40 PM logoCorMedix Inc. Demonstrates Sensitivity of Emerging Global Health Threat Candida auris to Taurolidine - May 9 at 4:28 PM logoCorMedix Inc. to Report First Quarter 2017 Financial Results and Provide Business Update - May 5 at 4:43 PM logoRodman & Renshaw Cuts CorMedix Inc. (CRMD) Price Target to $5.00 - May 5 at 8:36 AM logoCorMedix (CRMD) Earning Somewhat Favorable Media Coverage, Report Shows - May 4 at 1:46 PM logoCorMedix Inc. Announces Closing of Public Offering of Common Stock and Warrants and Underwriter's Exercise in Full of Over-Allotment Option - May 3 at 9:28 PM logoImplied Volatility Surging for CorMedix (CRMD) Stock Options - May 1 at 4:25 PM logoVery Favorable Media Coverage Extremely Likely to Affect CorMedix (CRMD) Share Price - May 1 at 10:44 AM logoCorMedix Inc. Increases Previously Announced Public Offering to $12.1 Million - April 28 at 5:27 PM logoCorMedix Inc. Announces $10 Million Underwritten Public Offering - April 27 at 10:00 PM logoPositive Media Coverage Unlikely to Impact CorMedix (CRMD) Stock Price - April 27 at 5:22 PM logoCorMedix Inc. (CRMD) Upgraded at Zacks Investment Research - April 25 at 8:52 PM logoFBR & Co Reaffirms "Buy" Rating for CorMedix Inc. (CRMD) - April 25 at 4:17 PM logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of CorMedix, Inc. - April 25 at 12:02 PM logoCorMedix (CRMD) Getting Favorable News Coverage, Report Shows - April 24 at 3:36 PM logoCorMedix Inc. Reports Update on Neutrolin(R) Phase 3 LOCK-IT 100 Clinical Trial - April 20 at 4:39 PM logoCorMedix (CRMD) Given News Impact Rating of 0.44 - April 20 at 7:50 AM logoCorMedix (CRMD) Receives Daily Coverage Optimism Rating of 0.56 - April 14 at 10:52 AM logoCorMedix Inc. Secures First European Commercial Collaboration for Neutrolin(R) - April 12 at 4:30 PM logoETFs with exposure to CorMedix, Inc. : April 10, 2017 - April 10 at 4:21 PM logoAre Options Traders Betting on a Big Move in CorMedix (CRMD) Stock? - March 30 at 4:56 PM logoCorMedix Inc. (CRMD) Upgraded to Hold at Zacks Investment Research - March 27 at 9:02 AM logoCorMedix Inc. Makes NYSE MKT Section 610(b) Public Announcement - March 23 at 9:58 PM logoCorMedix Inc. (CRMD) Upgraded by Zacks Investment Research to Hold - March 21 at 7:33 PM logoCorMedix crushed after warning on cash - Seeking Alpha - March 18 at 4:19 PM logoMid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher - March 17 at 4:02 PM logoCorMedix Inc. Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update - March 17 at 4:02 PM logoCORMEDIX INC. Files SEC form 8-K, Results of Operations and Financial Condition - March 17 at 4:02 PM logoCorMedix's stock plunges after warning that it may run out of cash - March 17 at 4:02 PM logoCorMedix Inc. (CRMD) Scheduled to Post Earnings on Tuesday - March 13 at 8:23 AM logoCorMedix Inc. to Report Fourth Quarter and Full Year 2017 Financial Results and Provide Business Update - March 10 at 5:32 PM


This page was last updated on 7/23/2017 by Staff